BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 145,861 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 145,861 shares of the firm’s stock in a transaction that occurred on Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the transaction, the chief executive officer owned 8,122 shares of the company’s stock, valued at $2,484,925.90. This trade represents a 94.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Price Performance

ONC traded up $2.60 during midday trading on Tuesday, hitting $306.56. The stock had a trading volume of 446,980 shares, compared to its average volume of 275,519. The company has a market cap of $33.64 billion, a P/E ratio of 68.58 and a beta of 0.49. The business has a fifty day moving average of $290.24 and a 200 day moving average of $308.90. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, equities analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE purchased a new stake in BeOne Medicines in the second quarter worth $67,657,000. Man Group plc bought a new position in BeOne Medicines in the 2nd quarter worth $59,031,000. BNP Paribas Financial Markets bought a new position in BeOne Medicines in the 2nd quarter worth $38,337,000. First Trust Advisors LP lifted its position in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares during the period. Finally, Qube Research & Technologies Ltd bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $26,034,000. Institutional investors own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ONC. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Friday, July 3rd. Wall Street Zen lowered BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 6th. Royal Bank Of Canada raised their price target on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $390.92.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.